Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
最近の投稿
- 1
Top 15 Supportable Design Brands Coming out on top - 2Find the Force of The ability to understand anyone on a deeper level: Improving Mindfulness and Connections
- 3Step by step instructions to Pick the Right Dental specialist for Your Dental Inserts Technique
- 4Sound Maturing: Wellbeing Tips for Each Life Stage
- 5NASA probe captures stunning photos of Earth and moon on the way to infamous asteroid Apophis
- ‘Nahariya get ready’: Banner displaying Hezbollah threat mounted in Tehran’s Palestine Square
- People with depression can treat themselves at home with new device
- Volcanic eruption led to the Black Death, new research suggests
- A Couple of Reasonable Guitars for 2024
- What to know as New York City nurses strike for a 3rd day
- Investigate Something else for Less: Financial plan Travel Objections
- Find the Abilities Required for Advanced Advertising Position
- Full Supreme Court to hear challenge to Judicial Selection Committee law
- FDA approves Wegovy pill for weight loss
